HumeCare+ research and fine print
Hume Health Care LLC is the platform operator. Its terms say the Delaware company provides technology, administration, the mobile experience, devices when included, and nonclinical support, but does not practice medicine, employ physicians, prescribe, or dispense. Hume Health Corp operates the legally separate Hume Health consumer wellness app.
MDI Medical Group PC is the contracted Clinical Network. Independent MDI clinicians make evaluation, prescribing, and ongoing-management decisions. A first-party directory lists names and license numbers for Massachusetts, Rhode Island, and Vermont; it is not a complete nationwide roster and does not determine who will be assigned to a particular patient.
The marketing site and contract publish different Dover mailbox numbers for Hume Health Care LLC. The marketing footer lists 8 The Green #24578, while the terms list 8 The Green #19007. The discrepancy is preserved rather than choosing one as definitively controlling.
Current first-party pages also present different medical-leadership names. One page calls Aaron Carter chief medical officer, while the microdose page calls Noah Davis chief medical officer. Neither identity is used as an AllyRx quick fact because the pages do not reconcile the titles with each other or the patient-specific MDI roster.
The coverage page lists forty-six states plus Washington, D.C. Alabama, Arkansas, Louisiana, and Mississippi are explicitly unavailable. The terms correctly qualify availability by state licensure and clinical-network coverage, so the list should be checked again immediately before enrollment.
Only three current product-and-route combinations receive cards. Weekly compounded semaglutide injection and daily oral compounded semaglutide reuse exact catalog records. The weekly tirzepatide, vitamin B12, and glycine compound remains an unmapped card because a multi-ingredient formulation is not interchangeable with the reusable single-ingredient tirzepatide record.
Microdose positioning is not another therapy. The public page describes a lower-dose GLP-1 protocol, while the safety document discusses lower semaglutide and tirzepatide doses. Dose level, titration schedule, and marketing label stay consolidated under the actual medication and route.
The current catalog lists $199 per month for semaglutide injection, $199 per month for oral semaglutide, and $299 per month for the tirzepatide combination. It displays $299, $299, and $399 as struck-through anchors. No history or terms show that those higher figures are ordinary prices, so they are described but excluded from calculations.
One first-party microdose page says $199 for the first four-week supply and then $199 per month. The contract supports monthly, quarterly, semiannual, and annual billing intervals only as possible checkout configurations, not as published current prices. With one usable monthly amount per product, there is no honest multi-term average to calculate.
The listed monthly figures are not confirmed complete totals. The terms define a clinical consultation fee assessed at enrollment and every refill, exclude that fee from the results guarantee, and never state its amount. The terms also permit extra charges for particular medications, dosages, formulations, or fulfillment options.
Price disclosures conflict with the onboarding consent screen. That screen says there are no membership fees or surprise charges, the price stays the same at every dose, and the user will not be automatically rebilled. The terms call the payment an integrated membership fee, require automatic renewal, and reserve additional charges and future price changes.
The service is self-pay. The current terms say neither Hume nor the patient may seek payment from Medicare, Medicaid, TRICARE, Veterans Affairs benefits, private insurance, or another payer under the current flat-fee track. Marketing says HSA and FSA funds are accepted, but plan eligibility and reimbursement are not guaranteed.
Plans renew automatically at the then-current rate unless canceled. Cancellation must be completed through the web account or support email at least forty-eight hours before renewal. Prepaid-plan cancellation leaves access active through the paid term and does not create a prorated refund.
The public six-month promise and the contract guarantee are not the same. Marketing promises at least 10% weight loss within six months or a refund. The terms offer a 90-day refund only when an eligible first-time GLP-1 user has no measurable loss and satisfies strict logging, weigh-in, adherence, payment, and claim-timing requirements.
The contract excludes every consultation fee from a guarantee refund and voids eligibility after missed logs, a missed weekly weigh-in, early cancellation, account suspension, failure to follow recommendations, or clinician-directed discontinuation. The shipping policy separately says refunds are available only after an initial ineligibility decision, so the policy set is internally inconsistent.
If a clinician determines after the initial evaluation that no treatment is appropriate, the terms promise an automatic refund within ten business days. If a Hume Pod was included, the refund may require return of the device in original condition and may deduct its cost. The shipping policy also withholds the refund when ineligibility follows false, incomplete, or misleading health information.
The advertised care path begins with a short online assessment and health history. An independent clinician reviews eligibility, may use video, audio, messaging, or remote monitoring, and issues a prescription only when appropriate. Price selection appears within the onboarding application rather than on the main homepage.
No universal GLP-1 laboratory panel, cadence, or included laboratory price is published. The testosterone section describes two fasting morning lab kits, but the current privacy policy treats future hormone programs separately, so that workflow is not projected onto GLP-1 care.
Pharmacy partners are not named before intake. The terms say pharmacies control compounding, dispensing, formula availability, shipping, and price, and promise that users will receive a choice of partners. Patients should confirm the assigned pharmacy, complete formula, salt form, concentration, quantity, storage, and beyond-use date before payment or use.
Formula copy is inconsistent. The product catalog names tirzepatide with vitamin B12 and glycine, while its benefit bullets also reference vitamin B6. Other pages broadly say glycine, B12, and B6 are built into the protocol or optional when appropriate. The exact patient-specific additives cannot be inferred from those marketing statements.
The shipping policy says clinician review typically takes one to two business days, pharmacy processing three to five business days, and medication then travels by two-day delivery through FedEx, UPS, or USPS. Tracking appears in the portal, and damaged or compromised packages should be reported with photos within twenty-four hours.
Homepage copy promises free next-day delivery, which does not match the longer written processing sequence. The policy makes delivery estimates conditional on pharmacy volume, carriers, weather, and other factors. It says HumeCare+ will investigate and arrange a replacement where applicable rather than promising an automatic replacement in every case.
General support uses support@humecare.com. The shipping policy lists support seven days a week from 8 AM to 8 PM Eastern, and the app routes clinical conversations to the relevant entity after separate consent. Checkout claims 24/7 clinical support, but it does not publish a response-time target, phone number, or live-staffing definition.
The privacy policy says Hume Care is not a HIPAA covered entity and that its current healthcare-provider partner is not one. Hume says it voluntarily adopts HIPAA-like safeguards, but voluntary practices are not the same as HIPAA covered-entity status. Clinical records remain with the provider rather than Hume Care.
Account linking and wellness-data sharing between Hume Health and Hume Care are user-initiated. Users can choose automatic, ask-me, or off settings. Medication name, dose, and schedule may flow to the wellness app, while user-entered dose and side-effect logs may return as self-attested data. Hume Pod outputs are wellness estimates, not diagnostic measurements.
The Pro.f AI feature is described as generating conversation prompts for clinical appointments, not diagnosing or changing treatment. The policy says these suggestions are generated in real time, not stored, and not used for model training. All medical decisions remain with the independent clinician.
HumeCare+ retains sensitive health information for a stated eleven-year period, nonclinical data for at least three years after account termination or the last clinical encounter, and de-identified information as needed for its stated purpose. De-identified data may be licensed to research organizations, pharmaceutical manufacturers, academic institutions, and analytics companies.
The site presents ratings ranging from 4.7 to 5.0 with differing review counts, weight-loss outcomes from different internal cohorts, and muscle-preservation comparisons without a complete independent audit trail. These are attributed provider claims and are not imported as AllyRx ratings or clinical-performance evidence.
A United States marketing page places logos for the General Pharmaceutical Council, Care Quality Commission, and MHRA under a regulated-by heading. Those are United Kingdom bodies, and the page does not explain how they apply to Hume Health Care LLC, MDI Medical Group PC, or U.S. dispensing pharmacies. U.S. licenses and the patient-specific pharmacy remain the relevant checks.
The site says compounded semaglutide is produced in an FDA-registered facility. Registration does not mean a compounded preparation or pharmacy is FDA approved. FDA says compounded GLP-1 products do not receive premarket review and recommends a patient-specific prescription filled by a state-licensed pharmacy when an approved drug cannot meet the patient's medical need.
The medication safety document identifies the compounded injections as weekly subcutaneous products and includes meaningful warnings. It also makes broad lower-dose benefit statements involving cardiovascular, inflammatory, gastrointestinal, neurodegenerative, and substance-use outcomes. Those claims are not converted into treatment indications or separate therapy cards.
The terms apply New York law, require sixty days of informal dispute resolution, mandate individual AAA commercial arbitration in New York City unless a new user opts out within thirty days, waive class and jury proceedings, impose a one-year claim limit, and cap liability at the greater of $100 or fees paid over the prior twelve months where enforceable.
HumeCare+ offers a distinctive combination of clinician care, app workflows, and wellness-device context. The decision should still turn on the written checkout total, exact medication label, assigned clinician and pharmacy, renewal date, guarantee eligibility, and shipping instructions rather than headline ratings, struck-through prices, or protocol branding.
- Three cards preserve active ingredient and route without creating therapies from protocol names or dose levels.
- Single monthly catalog figures stay compact, while an undisclosed recurring consultation fee prevents complete-price claims.
- The six-month 10% marketing promise conflicts with a much narrower 90-day contract guarantee.
- Automatic-renewal terms directly conflict with a funnel acknowledgement promising no automatic rebilling.
- MDI Medical Group PC, state coverage, and a limited provider directory are publicly identified.
- Shipping and privacy policies are unusually detailed, including carriers, damage timing, data flows, and retention.
- Pharmacy identity, exact formulas, and complete checkout totals remain unresolved before intake.
- Conflicting leadership, ratings, addresses, delivery promises, and U.K. regulator imagery reduce trust.
